Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wenyang Tongbi Formula for Chemotherapy-Induced Polyneuropathy
NCT07626528Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall Response Rate at 42 days. Planned start Jul 2026; status: not yet recruiting.
02
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07626528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07626528.